"We should be pouring money and time into hemp, Period."

Forbes

2018 Farm Bill - Hemp Legalization Text

The Federal Government Legalizes Hemp and Hemp CBD Production

The 2018 Farm Bill was passed with specific language that not only separates Hemp and Hemp Derived products from the Controlled Substance Act, it also paved the road to retail sale of Hemp CBD products by giving freedom to ship products nationwide and the possibility of cultivation, manufacturing, and selling of Hemp CBD products if the state allows.

NOTE: The FDA Still has authority over CBD Products. The FDA has not given permission to companies to sell indigestible products as of July 2019. Read the article on the FDA policies and meetings below.

FDA on CBD

Updated March 2020

There is a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including cannabidiol (CBD). FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significant interest in these possibilities. However, FDA is aware that some companies are marketing products containing cannabis and cannabis-derived compounds in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act) and that may put the health and safety of consumers at risk. The agency is committed to protecting the public health while also taking steps to improve the efficiency of regulatory pathways for the lawful marketing of appropriate cannabis and cannabis-derived products. FDA has a number of resources available that address cannabis and cannabis-derived products, such as CBD, and the agency wants to ensure that consumers and other stakeholders have access to these resources in a centralized location.

USDA on CBD

Updated March 2020

The Agriculture Improvement Act of 2018 (2018 Farm Bill) authorized the production of hemp and removed hemp and hemp seeds from the Drug Enforcement Administration’s (DEA) schedule of Controlled Substances. It also directed the U.S. Department of Agriculture (USDA) to issue regulations and guidance to implement a program to create a consistent regulatory framework around production of hemp throughout the United States. The establishment of hemp as a regulated commodity also paves the way for U.S. hemp farmers to participate in other USDA farm programs.

This rule is a first step that enables the Farm Service Agency (FSA), Natural Resources Conservation Service (NRCS), and Risk Management Agency (RMA) to provide guidance on eligibility for farm programs. Once production plans are approved and licenses are issued, hemp producers may be eligible for many USDA programs in 2020, including:

Whole-Farm Revenue Protection (WFRP)

Noninsured Crop Disaster Assistance Program (NAP)

NRCS-administered conservation programs, including the Environmental Quality Incentives Program, Conservation Stewardship Program, Regional Conservation Partnership Program, and Agricultural Conservation Easement Program

Farm loans, including operating, ownership, beginning farmer, and farm storage facility

FDA is Committed to Sound, Science-based Policy on CBD

U.S. Food and Drug Administration

We recognize that there is significant public interest in these products, for therapeutic purposes and otherwise. At the same time, there are many unanswered questions about the science, safety, and quality of many of these products.

Information on CBD Data Collection and Submission

U.S. Food and Drug Administration

FDA encourages stakeholders to submit comments, data, and information related to CBD to the public docket, which FDA reopened on March 11, 2020. FDA reopened this docket to provide a public and transparent way for stakeholders to provide new and emerging information to us in real time as it becomes available. In the notice reopening the public docket, FDA outlined areas where data would be useful to inform FDA on the safety of CBD.

FDA and Cannabis: Research and Drug Approval Process

U.S. Food and Drug Administration

To date, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. The agency has, however, approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These approved drug products are only available with a prescription from a licensed healthcare provider. Importantly, the FDA has not approved any other cannabis, cannabis-derived, or cannabidiol (CBD) products currently available on the market.

FDA REGULATION OF DIETARY SUPPLEMENT & CONVENTIONAL FOOD PRODUCTS CONTAINING CANNABIS AND CANNABISDERIVED COMPOUNDS

U.S. Food and Drug Administration

With the increasing popularity of products containing cannabis and cannabis-derived compounds (including cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)), FDA is aware that some companies are marketing conventional food products and products labeled as dietary supplements that contain cannabis or cannabis-derived compounds in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act). Here is what you need to know about FDA’s regulation of these types of products.

FDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market Clarity

U.S. Food and Drug Administration

Over the past year, the U.S. Food and Drug Administration has embarked on a comprehensive evaluation of cannabidiol (CBD) products, with a focus on educating the public about the risks and unknowns of these products, gathering the science needed to better understand both these safety concerns and potential benefits to inform our regulatory approach, as well as taking steps when necessary to address products that violate the law in ways that raise a variety of public health concerns.

Today, we are providing updates on our efforts in this area, including several new steps in areas of education, research and enforcement with the ultimate goal of continuing to protect the public health and working to provide market clarity.

FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns

U.S. Food and Drug Administration

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. Based on the lack of scientific information supporting the safety of CBD in food, the FDA is also indicating today that it cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for its use in human or animal food.

Remarks at the National Industrial Hemp Council 2019 Hemp Business Summit

U.S. Food and Drug Administration

There’s a lot going on these days in the world of hemp, including at the U.S. Food and Drug Administration (FDA). We’ve seen an explosion of interest in hemp and hemp-derived products, as well as some important changes to the legal landscape. And increasingly, we’ve been hearing from a broad range of stakeholders who are eager to better understand where FDA fits into all of this, how our authorities apply to hemp and hemp products, and what the future has in store.

What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

U.S. Food and Drug Administration

The FDA is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.